Literature DB >> 28417664

Low-dose systemic scopolamine disrupts context conditioning in rats.

Laura Luyten1, Shauni Nuyts1, Tom Beckers1.   

Abstract

Cholinergic neurotransmission plays a key role in learning and memory. Prior research with rats indicated that a low dose of pre-training scopolamine (0.1 mg/kg), a cholinergic receptor antagonist, did not affect cued fear conditioning, but did block renewal when injected before extinguishing a conditioned tone, opening up opportunities to pharmacologically improve exposure therapy for anxiety patients. Before translating these findings to the clinic, it is important to carefully examine how scopolamine affects contextual fear memories. Here, we investigated the effects of scopolamine on encoding of contextual anxiety and its generalization in male Wistar rats. We found a profound disruption of context conditioning, suggesting that, even at a low dose, systemic scopolamine may influence contextual encoding in the hippocampus, particularly when the context is the best predictor for the presence of shocks.

Entities:  

Keywords:  Context conditioning; anxiety; contextual fear; generalization; rats; scopolamine

Mesh:

Substances:

Year:  2017        PMID: 28417664      PMCID: PMC5462095          DOI: 10.1177/0269881117699614

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  31 in total

1.  Intrahippocampal scopolamine impairs both acquisition and consolidation of contextual fear conditioning.

Authors:  G V Wallenstein; D R Vago
Journal:  Neurobiol Learn Mem       Date:  2001-05       Impact factor: 2.877

2.  A contemporary learning theory perspective on the etiology of anxiety disorders: it's not what you thought it was.

Authors:  Susan Mineka; Richard Zinbarg
Journal:  Am Psychol       Date:  2006-01

Review 3.  Contextual conditioning in rats as an animal model for generalized anxiety disorder.

Authors:  Laura Luyten; Debora Vansteenwegen; Kris van Kuyck; Loes Gabriëls; Bart Nuttin
Journal:  Cogn Affect Behav Neurosci       Date:  2011-06       Impact factor: 3.282

Review 4.  The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies.

Authors:  Inge Klinkenberg; Arjan Blokland
Journal:  Neurosci Biobehav Rev       Date:  2010-04-14       Impact factor: 8.989

Review 5.  Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory.

Authors:  E A van der Zee; P G Luiten
Journal:  Prog Neurobiol       Date:  1999-08       Impact factor: 11.685

6.  Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

Authors:  David L Walker; Kerry J Ressler; Kwok-Tung Lu; Michael Davis
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

7.  Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear.

Authors:  D L Walker; M Davis
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

8.  Olfactory fear conditioning paradigm in rats: effects of midazolam, propranolol or scopolamine.

Authors:  Juliana A V Kroon; Antonio Pádua Carobrez
Journal:  Neurobiol Learn Mem       Date:  2008-12-16       Impact factor: 2.877

Review 9.  Muscarinic cholinergic influences in memory consolidation.

Authors:  Ann E Power; Almira Vazdarjanova; James L McGaugh
Journal:  Neurobiol Learn Mem       Date:  2003-11       Impact factor: 2.877

10.  No effect of glucose administration in a novel contextual fear generalization protocol in rats.

Authors:  L Luyten; N Schroyens; K Luyck; M S Fanselow; T Beckers
Journal:  Transl Psychiatry       Date:  2016-09-27       Impact factor: 6.222

View more
  4 in total

1.  Cholinergic Modulation of Exposure Disrupts Hippocampal Processes and Augments Extinction: Proof-of-Concept Study With Social Anxiety Disorder.

Authors:  Michelle G Craske; Michael Fanselow; Michael Treanor; Alexander Bystritksy
Journal:  Biol Psychiatry       Date:  2019-04-19       Impact factor: 13.382

2.  Endogenous in-session cortisol during exposure therapy predicts symptom improvement: Preliminary results from a scopolamine-augmentation trial.

Authors:  Kate R Kuhlman; Michael Treanor; Gabriella Imbriano; Michelle G Craske
Journal:  Psychoneuroendocrinology       Date:  2020-03-20       Impact factor: 4.905

Review 3.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

4.  Exposure Therapy for Post-Traumatic Stress Disorder: Factors of Limited Success and Possible Alternative Treatment.

Authors:  Sara Markowitz; Michael Fanselow
Journal:  Brain Sci       Date:  2020-03-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.